According to the research report, the global monkeypox testing market was valued at USD 1,331.48 million in 2021 and is expected to reach USD 1,968.47 million by 2030, to grow at a CAGR of 4.5% during the forecast period.
Market Overview
Monkeypox, a rare viral disease belonging to the Orthopoxvirus genus, has resurfaced in multiple regions across the globe. Initially endemic to Central and West Africa, the disease gained global attention due to rising international cases starting in 2022. The resultant increase in infection rates, travel-linked transmissions, and potential public health risks has compelled nations to enhance their viral infection containment capabilities through robust diagnostic frameworks.
The Monkeypox Testing Market has grown significantly in recent years, driven by:
- The need for early detection and containment of outbreaks.
- Rising investment in public health infrastructure.
- Technological advancement in real-time PCR testing methods.
- Increased awareness of zoonotic diseases and global health security.
This evolving landscape is further shaped by the need for outbreak surveillance testing to track and monitor the virus’s transmission dynamics in both endemic and non-endemic regions.
Key Companies in the Monkeypox Testing Market
The monkeypox testing landscape is dominated by global diagnostic giants, alongside several emerging biotech firms developing novel detection solutions.
- Aegis Sciences Corp
- BD
- Chembio Diagnostics Inc.
- Laboratory Corp. of America Holdings
- Mayo Clinic Laboratories
- QIAGEN
- Quest Diagnostics Inc
- Sonia Healthcare Ltd
- Sonora Quest Laboratories
- Thermo Fisher Scientific
Global Market Trends: Country-Wise Analysis
United States
The United States has been at the forefront of developing response strategies to emerging infectious diseases, including monkeypox. Following multiple confirmed cases across states in recent years, the U.S. Centers for Disease Control and Prevention (CDC) and associated laboratories ramped up orthopoxvirus diagnostics capabilities.
Key market trends in the U.S. include:
- Expanded lab networks using real-time PCR testing for early detection.
- Integration of outbreak surveillance testing into existing public health databases.
- Federal and state-level initiatives to scale mobile testing labs in response to regional spikes.
These advancements have propelled the U.S. to maintain a proactive role in the global Monkeypox Testing Market, focusing on preparedness and rapid containment protocols.
United Kingdom
In the UK, a rise in imported and community transmission cases prompted immediate government intervention and mass testing efforts. Public health authorities prioritized the enhancement of lab capabilities and bolstered the supply chain for testing reagents.
Trends specific to the UK market include:
- Focused deployment of viral infection containment programs in urban hubs.
- Use of real-time PCR testing in both hospital and community health settings.
- Partnerships between regional health bodies and national labs for better data integration.
The UK continues to strengthen its outbreak surveillance testing network, using it as a foundation to control future waves of the disease or its variants.
Germany
Germany has shown a data-driven approach to managing monkeypox outbreaks. By embedding orthopoxvirus diagnostics into existing disease monitoring systems, the country has ensured early detection and improved contact tracing outcomes.
Notable market trends in Germany:
- Development of specialized training for laboratory personnel in real-time PCR testing protocols.
- Integration of monkeypox screening into general viral panel diagnostics for travelers.
- Regional public health authorities allocating funds toward high-throughput testing machines.
Germany’s focus on viral infection containment through diagnostic readiness and public awareness continues to contribute to the market’s upward trajectory in the region.
India
India’s response to monkeypox has shifted from reactive to preventive, with heightened efforts in early detection and resource allocation. As a country with vast geographic and demographic diversity, India faces unique challenges in rolling out consistent diagnostic access.
Emerging market trends in India:
- Expansion of outbreak surveillance testing capabilities in both metropolitan and rural areas.
- Scaling of real-time PCR testing infrastructure through state-supported health programs.
- Integration of monkeypox testing into airport and immigration screening points.
Given the country’s ongoing investment in healthcare digitization and pandemic response mechanisms, India is poised to become a significant contributor to the global Monkeypox Testing Market.
Brazil
Brazil, with its extensive biodiversity and history of zoonotic outbreaks, has increasingly recognized the threat posed by monkeypox. Recent confirmed cases have led to a public health shift in diagnostic preparedness.
Key developments in Brazil’s testing landscape:
- Deployment of orthopoxvirus diagnostics in both private and public laboratories.
- Strengthening of outbreak surveillance testing in vulnerable and indigenous communities.
- Enhancement of rapid diagnostic kits alongside conventional PCR techniques.
Brazil’s focus on environmental factors contributing to zoonotic spillovers highlights its strategic approach to viral infection containment.
South Africa
South Africa’s role in the Monkeypox Testing Market is becoming increasingly vital due to its surveillance infrastructure and previous experience managing infectious disease outbreaks such as HIV and COVID-19.
Country-specific trends include:
- Public-private collaborations to extend real-time PCR testing beyond urban centers.
- Expansion of outbreak surveillance testing in wildlife regions and areas bordering Central Africa.
- Government grants aimed at improving laboratory biosafety and testing throughput.
South Africa is actively seeking to bridge the diagnostic gap between urban hospitals and rural clinics to ensure equitable response capabilities across the population.
France
France has adopted a centralized and digitalized approach to infectious disease diagnostics. With monkeypox added to its list of notifiable diseases, laboratories across the nation have scaled up orthopoxvirus diagnostics capabilities.
Market insights from France include:
- Deployment of real-time PCR testing in public health laboratories and academic medical centers.
- Integration of testing results with centralized health platforms for better outbreak surveillance.
- Focus on rapid reporting and contact tracing as tools for viral infection containment.
France continues to invest in lab innovation and mobile testing units as part of its broader national strategy against zoonotic threats.
Nigeria
As one of the endemic countries for monkeypox, Nigeria has long dealt with the challenges of detection, tracking, and containment. The country is seeing renewed support from international health agencies to bolster its diagnostic capabilities.
Noteworthy market trends in Nigeria:
- Expansion of regional laboratories capable of performing orthopoxvirus diagnostics.
- Emphasis on community-based outbreak surveillance testing, particularly in forested zones.
- Efforts to introduce rapid real-time PCR testing solutions in lower-resource settings.
Nigeria’s approach underscores the importance of early testing in limiting the spread within communities and to international regions.
Canada
Canada’s approach to monkeypox testing has focused on integrating diagnostic readiness with national health surveillance platforms. With increasing international travel and rising awareness, testing for monkeypox is becoming more commonplace in clinical practice.
Current market developments in Canada:
- Nationwide deployment of real-time PCR testing kits through public health labs.
- Use of outbreak surveillance testing to track epidemiological data across provinces.
- Investments in public education campaigns to support viral infection containment through early detection.
Canada’s market is growing steadily, reflecting a proactive rather than reactive stance toward emerging infectious diseases.
Explore More:
https://www.polarismarketresearch.com/industry-analysis/monkeypox-testing-market
Conclusion
The global Monkeypox Testing Market is entering a new phase of maturity and scale as countries across the economic spectrum strengthen their diagnostic ecosystems. Whether driven by firsthand outbreaks or preventive health policy, the emphasis on accurate, fast, and scalable orthopoxvirus diagnostics is reshaping public health strategies worldwide.
Real-time PCR testing remains the gold standard, enabling high-precision results and timely containment. In parallel, outbreak surveillance testing is being integrated into broader pandemic preparedness frameworks, allowing for data-informed interventions.
From Brazil’s rainforest regions to Germany’s high-tech labs, the overarching priority remains the same: rapid viral infection containment through strategic testing initiatives.
As global interconnectivity increases, so too does the importance of harmonized diagnostic approaches. The continued evolution of the Monkeypox Testing Market is not just a response to a single disease—it is a marker of how nations prepare for the next public health frontier.
More Trending Latest Reports By Polaris Market Research:
FEP Heat Shrink Medical Tubing Market
High-speed Data Converter Market
Hematology Analyzers and Reagents Market
